

DRUG ELUTING STENTS AND BALLOONS***Tupe Ravindra, Gade Snehal, Karpe Manisha, Kadam Vilasrao**

Bharati Vidyapeeth's College of Pharmacy, Sector 8, C.B.D. Belapur, Navi Mumbai- 400614.

*For Correspondence: Bharati Vidyapeeth's College of Pharmacy, Sector 8, C.B.D. Belapur, Navi Mumbai- 400614.	ABSTRACT A little work like gadget made of metal goes about as a backing or framework, in keeping the vessel open. An angioplasty inflatable is a therapeutic gadget that is embedded into an obstructed conduit and swelled to clear blockage and permit blood to stream. Stent and inflatable serves to enhance blood stream to the heart muscle and diminish the torment of angina, 80% of patients who have inflatable angioplasty will have a stent set too. Drug eluting stents (DES) and Drug eluting inflatable has reformed the field of interventional cardiology by demonstrating its security and viability to avoid restenosis of coronary veins utilizing neighborhood drug conveyance. In the meantime, neighborhood drug conveyance utilizing a medication eluting stent and inflatable offers the point of preference of permitting high neighborhood groupings of medication at the treatment site while minimizing systemic dangerous impacts. Biodegradable polymers have been utilized as a part of controlled medication conveyance for a long time. These biodegradable polymers debase inside the body as a consequence of normal organic forms, taking out the need to evacuate a medication conveyance framework after arrival of the dynamic specialist has been finished. Generally, the price of a DES is at least three-fold higher than the price of a conventional bare metal stent. The advent of more varieties of DES in near future will minimize the cost issue and make DES available to all patients.
Received: 13.02.2017 Accepted: 22.03.2017	
Access this article online	
Website: www.drugresearch.in	
Quick Response Code: 	

INTRODUCTION

The Expression "stent" was initially utilized as a part of 1917 to portray an aggravate that makes a structure for facial recreation. Presently it is utilized to show any gadget utilized for developing, extending, or settling in an extended state. Therefore, this audit concentrates on the different constituents of medication conveyance stents, which incorporate the stent spine, the materials utilized as medication conveyance vehicles, and the physicochemical properties of the pharmacotherapeutic operators themselves. The idea of utilizing stents as vehicles for the drawn out and adequate conveyance of medications is engaging. Stents speak to a perfect stage for nearby medication conveyance on account of their changeless framework properties that counteract vessel backlash and negative renovating. What's more, the stents speak to medication supplies, in as much as prescriptions are discharged from different coatings at various time interims. The expression "stent" gets from a dental prosthesis created by the London dental specialist Charles stent (1807-1885), demonstrates any gadget utilized for amplifying, extending or altering in an extended state. The primary stent was embedded in human coronary supply routes in 1986 by Ulrich Sigwart, Jacques Puel, and their partners, who set the dividers stent sheathed self-extending metallic cross section framework in the fringe and coronary arteries.[1]

Charles Dotter, explored the expansion of limited supply routes by method for catheters in the 1960s. Dotter opened limited leg supply routes by passing dynamically bigger catheters through

them. Dotter's work was taken up in Europe, in spite of the fact that it got little consideration in the United States. An inflatable catheter for opening the iliac supply route (at the highest point of the leg) was created in 1973 by a Dr. Porstmann. Dr. Andreas Gruentzig, working at the University Hospital of Zurich in Switzerland, is credited with playing out the principal inflatable angioplasty to open a stopped up coronary supply route. Gruentzig worked all through the 1970s culminating an inflatable catheter that was slim and sufficiently adaptable to carry out the employment. In 1977, he played out his first methodology. The patient endured angina because of a solitary blocked supply route. Gruentzig played out the operation with a group of specialists remaining by to do a crisis sidestep if the operation fizzled. In any case, the angioplasty was effective. Gruentzig taught the procedure to others, and brought his innovation to the United States when he emigrated to Atlanta, Georgia, in 1980. Gruentzig kicked the bucket in a plane accident in 1985, yet inside 10 years of his presentation of angioplasty, the strategy was being performed on more than 200,000 patients yearly. That number rose throughout the following decade as the method was refined, and better medicine medications were found to avert scarring after the expansion.[2]

Stent

A stent is a little, work like gadget made of metal. At the point when a stent is put within a coronary conduit, it goes about as a backing or platform, keeping the vessel open. By keeping the vessel open, the stent enhances blood stream to the heart muscle and decrease the agony of angina. Stent techniques are generally utilized alongside inflatable angioplasty. Truth be told, around 80% of patients who have inflatable angioplasty will have a stent set too. [1]



FIG 1- Stent.

Balloons

An angioplasty inflatable is a restorative gadget that is embedded into a stopped up course and expanded to clear blockage and permit blood to stream.[3]



FIG 2- Balloon

Classification of stents and balloons:

Stent:

1. Uncovered metal stent; (stainless steel stent, cobalt chromium stent)
2. Drug eluting stent
 - A) first era stent (figure, taxus)
 - second era stent (xience, try)
 - third era stent (promus)
 - B) Bio-absorbable medication eluting stent (stents made of polymer)

Balloon:

1. High pressure balloon
2. low pressure balloon
3. Drug eluting balloon

STENTS

1. Bare -metal stent

It is a vascular stent with no covering. It is a cross section like container of slim wire. The primary stents authorized for use in cardiovascular corridors were exposed metal - 316L stainless steel.

Stainless steel stent

It comprises of 0.030-cm stainless steel wire framed in a crisscross example. Every band is welded with silver to shape an eyelet. The wires bend tied through the eyelet with monofilament nylon suture. [4]

Cobalt chromium stent

It has high adaptability and spiral quality contrasted with stainless steel stent and it is additionally radio-misty. Stent lengths of 8, 12, 13, 15, 18, 23, and 28mm and breadth of 3.0, 3.5, 4.0mm were accessible. [5]

2. DRUG ELUTING STENT (DES)

DES is a fringe or coronary stent (a framework) put into contracted, ailing fringe or coronary conduits that gradually discharges a medication to piece cell multiplication. This anticipates fibrosis. The stent is generally set inside the fringe or coronary corridor amid an angioplasty methodology. Drug-eluting stents in current clinical use were affirmed by the FDA after clinical trials demonstrated they were measurably better than exposed metal stents for the treatment of local coronary supply route

narrowing. The primary medication eluting stents to be endorsed in Europe and the U.S. were covered with paclitaxel and sirolimus.

Drug eluting stents are sorted as;

(a) First era (cypher, taxus)

Cypher stent and Taxus stent is comprised of 316L stainless steel, covered with against proliferative specialist, sirolimus and paclitaxel which avoids neointimal hyperplasia.

(b) Second era stent (xience, endeavor)

Xience stent and endeavor stent is comprised of cobalt chromium, it has high adaptability, high spiral quality contrasted with stainless steel stent, furthermore radio-hazy, it is covered with zotarolimus and everolimus, anticipates neointimal hyperplasia.[4][5][6][7].

(c) Third era stent (promus)

Promus stent is made of platinum, stent strut thickness is less when contrasted with first and second era stent which causes less vascular damage which diminishes the rate of neointimal development, in this manner diminishes the rates of resulting restenosis. Promus stent is covered with everolimus.[8][9].

Neointimal Hyperplasia.

It is strange expansion in the quantity of cells bringing about a thickness of vein. Brought on by platelets that are pulled in by the harmed tissue created by the situation of a stents. Tissue becomes through the opening of stent and strait the lumen of vessel, consequently lessening myocardial blood stream, this is additionally called as restenosis.





Table-1. Comparison of stent platform specifications among current drug-eluting stents.[10]

	Design Elements			
Specification stent platform	Pattern	Material	CoCr Strut thickness (height)(mm)	Strut width (mm)

Promus /Taxus Element		PtCr	0.081 (0.086 for ≥ 4.0 mm diameter)	0.061 (small vessel) 0.089 (large vessel)
Taxus Liberté stent platform		316L-SS	0.097	Min: 0.076 Max: 0.094
Promus (XienceV) Stent platform		L605 CoCr	0.081	0.076
Cypher stent platform		316L-SS	0.140	Min: 0.081 Max: 0.132
Endeavor stent platform		MP35N CoCr	0.090	0.090




FIG-4 Inter-relationship between features of stent design, procedural outcomes, and clinical outcomes. [11]

Bio-absorbable medication eluting stent

Bio-absorbable DES is a gadget that could accomplish great intense and long haul results, yet itself get vanish totally inside months, in this way evading the requirement for delayed double hostile to platelet treatment. These biodegradable stents, which are made of polymers or metal composites with or without a medication covering, can possibly framework the corridor to permit normal recuperating to happen, and after that biodegrade.[12].




FIG-5 Biodegradable stents

Non-degradable polymers:

Polyurethane, polymethacrylate, silicone, polyorganophosphacene, polymethacrylate, polyethylene terephthalate, and phosphorylcholine.

Degradable polymers:

Polylactide, polyhydroxybutyrate, hyaluronic acid, polycaprolactone, polyorthoester, and fibrin.[13][14][15].

STENT DELIVERY

High-weight inflatables are ordinarily used to send and present expand stents on decrease the rate of blood vessel restenosis and intense re-conclusion taking after angioplasty. Stents are metallic frameworks embedded to bolster the dividers of corridors and other body pits. Coronary stents, machined metal tubes or wire cross section, are creased over an inflatable and embedded into the range of a blockage after angioplasty. Swelling the inflatable opens the stent, which stays extended to keep the vessel open. The utilization of high-weight inflatables permits the doctor to completely grow the stent until it is in full contact with the blood vessel divider. The utilization of a low consistence inflatable permits the additional certainty that the stent and the course won't be over extended and additionally the inflatable won't over-grow the supply route on either end of the stent. The stent stays in position after the inflatable is flattened and expelled from the body.[16]

Point of preference of medication eluting stent over bare metal stent

- Sirolimus is a medication used to keep the body from dismissing organ and bone marrow transplants.
- It limits typical tissue excess (restenosis) taking after coronary stent implantation.
- The polymer permits the medication to be discharged more than 30 days which diminished restenosis impacts.
- The drug Paclitaxel is an antineoplastic operator that restrains cell relocation and expansion covered with a polymer concoction compound called Transulte.
- These clinical trials have demonstrated that paclitaxel-eluting stents decrease restenosis and the requirement for revascularization with a nonpartisan impact on mortality and myocardial localized necrosis hazard.

Disadvantage of metal stent

- Causes lasting physical aggravation.

- Risk of long haul endothelial brokenness and ceaseless aggravation.
- Metal have thrombogenic properties.
- Inability for the vessel to reestablish its ordinary physiology.

BALLOONS

An angioplasty inflatable is a medicinal gadget that is embedded into a stopped-up conduit and expanded to clear blockage and permit blood to stream

THREE BASIC TYPES OF MEDICAL BALLOONS

Three basic types of balloons are used

1. High pressure balloon
2. Low pressure balloon
3. Drug eluting balloon

High pressure balloon: It is non-versatile, dilatation or angioplasty-sort inflatable used to apply power. High-weight inflatables are formed to their swelled geometry from resistant or lowcompliant materials that hold their outlined size and shape even under high weight. They are slight walled and display high elasticity with moderately low stretching.

Table-2 Comparison of High-Pressure Balloons Made with Various Materials

Materials	PET	Nylons	PE(cross linked) and other poly-olefins	Polyurethanes	PVC (flexible)
Tensile Strength	High-very high	Medium-high	Low	Low-medium	Low
Compliance	Low-medium	Medium	High	Medium-high	High
Stiffness	High	Medium	Low	Low-medium	Low
Sterilization Methods	EtO or Radiation	EtO	EtO or Radiation	EtO	Radiation

APPLICATIONS OF HIGH-PRESSURE BALLOONS

USE OF HIGH-PRESSURE BALLOONS

DILATATION

Angioplasty is the most broadly utilized utilization of high-pressure balloons. Dilatation inflatables are utilized to widen and unblock supply routes that nourish the heart in percutaneous transluminal coronary angioplasty (PTCA). Common sizes of inflatables for PTCA catheters range in size from 2 to 4 mm in distance across 10 to 40 mm long, and are evaluated for a weight capacity of 10-20 ATM. For (non-coronary) percutaneous transluminal angioplasty (PTA), inflatable sizes regularly run from 4 to 12 mm in distance across and 20 to 100 mm long. Evaluated weights for PTA 8-20 ATM. PTA techniques incorporate expansion of courses other than the coronary supply routes. High-weight inflatables are additionally utilized and being created to expand limitations and blockages basically anyplace in the body. These utilizations include:

Esophageal dilatation

Biliary dilatation
Urethral dilatation
Fallopian tube dilatation
Heart esteem dilatation
Tear channel dilatation and some more.

Low pressure balloon: It is elastomeric swell commonly made of latex or silicone that is utilized essentially as a part of obstruction and impediment. Low-weight inflatables are normally dipmolded fit as a fiddle which is then extended a few times its unique size being used, in this way these inflatables can't be expanded to exact measurements or hold all around characterized shapes and high weights. For angioplasty, inflatables must have a controlled or repeatable size (distance across versus weight) in request to guarantee that the inflatable won't proceed to grow and harm or burst the course after it opens the blockage. Inflatable consistence is the term used to portray the degree to which a high-weight balloon's breadth changes as a component of weight. A low-compliance, high-weight inflatable may grow just 5 – 10% when swelled to the appraised weight while a high-consistence, high-weight inflatable may extend 18 – 30%. Then again, low-weight elastomeric inflatables, which are swelled by volume, not weight, can extend 100 – 600%. At the point when the weight is discharged, elastomeric inflatables recoup near their unique size and shape. They as a rule can't be utilized to apply high weight in therapeutic applications

Drug eluting balloon: DEB convey higher paclitaxel measurements (300 to 600ug with DEB versus 100 to 200ug with DES), what's more, as the medication eluting stent struts usually cover just 20% of the harmed vessel divider, the bigger DEB surface region ensures more uniform medication conveyance [17].

Concept of the drug-eluting balloon

Restenosis because of neointimal hyperplasia is a moderate procedure, proposing that drawn-out neighborhood drug organization would be should have been advantageous. Stent-based neighborhood drug conveyance gives managed drug discharge utilizing exceptional discharge advancements, for example, polymer coatings. Supported medication discharge is by all accounts vital for stent based neighborhood drug discharge because of the inhomogeneous medication dissemination from DES to the blood vessel divider. Thus, generally high drug fixation on the stent struts including a controlled and managed discharge are required for stent-based neighborhood drug conveyance, which thus brings about deferred and inadequate endothelialization of the stent struts [18]

A late study showed that even short contact between vascular smooth muscle cells and lipophilic taxane mixes could repress vascular smooth muscle cell expansion for an augmented timeframe. Non-stent-based neighborhood drug conveyance, especially a DEB, could homogeneously manage the counter proliferative medication to the vessel divider. The medication focus at the vessel divider would be the most elevated at the season of harm when the neointimal procedure is the most overwhelming. What's more, the DEB is a consistent angioplasty inflatable requiring no extraordinary taking care of. The DEB hence speaks to a novel alternative for the treatment of coronary and fringe corridors and for high-hazard restenotic sores, for example, little vessels, bifurcations or in-stent restenotic injuries. Results from a porcine creature model study demonstrated that the medication covered on the inflatables of percutaneous transluminal coronary angioplasty or percutaneous transluminal catheters repressed neointimal hyperplasia. In this study, the most declared lessening of neointimal arrangement was seen with paclitaxel-covered inflatable catheters. [19][20][21]

BALLOON COATING

A wide variety of coatings can be added to the surface of a balloon to enhance or change its properties to meet new requirements. Balloon coatings include the following:

- Lubricious coatings
- Abrasion and puncture resistant coatings
- Tacky or high friction coatings
- Conductive coatings
- Anti-thrombogenic coatings
- Drug release coatings

USE OF DRUG ELUTING STENT AND BALLOON IN CORONARY ARTERY DISEASE

Atherosclerosis:

Atherosclerosis (here and there called "solidifying" or "stopping up" of the supply routes) is the development of cholesterol and greasy stores (called plaque) on the internal dividers of the corridors that confine blood stream to the heart. Atherosclerosis can influence the courses in the heart, legs, cerebrum, kidneys and different organs. Atherosclerotic coronary illness (coronary corridor malady) is the narrowing or blockage of the coronary (heart) courses. Your coronary corridors are formed like empty tubes through which blood can stream unreservedly. Typically, the dividers of the coronary courses are smooth and flexible. Atherosclerosis happens when the ordinary coating of the courses break down, the dividers of the courses thicken and stores of fat and plaque develop on the coronary corridor dividers, blocking alternately constraining the stream of oxygen-rich blood to the heart muscle without sufficient blood, the heart gets to be famished of oxygen and the fundamental supplements it needs to work appropriately. This can bring about mid-section torment called angina. When one or a greater amount of the coronary supply routes are totally hindered, a heart assault (damage to the heart muscle) may occur.[22][23][24].

Interventional technique.

An interventional technique is a non-surgical treatment used to open limited coronary supply routes to enhance blood stream to the blocked zones. An interventional strategy can be performed amid an indicative catheterization when a blockage is recognized, or it might be booked after a catheterization has affirmed the nearness of cluster. An interventional methodology begins the same route as a cardiovascular catheterization. Once the catheter is set up, one of these interventional systems is performed to open the artery by inflatable angioplasty or stent placement. [25]

Balloon angioplasty:

A system in which a little inflatable at the tip of the catheter is embedded close to the blocked or contracted region of the coronary supply route. The specialized name for inflatable angioplasty is percutaneous transluminal coronary angioplasty (PTCA) or percutaneous coronary intercession (PCI). At the point when the inflatable is expanded, the greasy plaque or blockage is packed against the supply route dividers and the measurement of the vein is augmented (expanded) to increment blood stream to the heart. This strategy is now and then entangled by vessel pull back and restenosis.[26]

Balloon angioplasty with stenting:

Balloon angioplasty is performed in blend with the stenting method. A stent is a little, metal lattice tube that goes about as a framework to give support inside the coronary course. A inflatable catheter, put over an aide wire, is utilized to embed the stent into the contracted supply route. Once set up, the inflatable is swelled and the stent extends to the measure of the supply route and holds it open. The inflatable is emptied and expelled, and the stent stays set up for all time. During a time of a few weeks, the artery mends around the stent. Along these lines, restenosis is fairly lessened. Angioplasty with stenting is most normally suggested for patients who have a blockage in maybe a

couple coronary corridors. On the off chance that there are blockages in more than two coronary conduits, coronary conduit sidestep join surgery might be recommended.[26]

Drug-eluting stents (DES):

Drug-eluting stents contain a medicine that is effectively discharged at the stent implantation site. Drug-eluting stents have a slim surface of pharmaceutical to lessen the danger of restenosis. It is important to take meds for a while after the technique to keep the danger of thickening in the stent.[27]

Cost effectiveness of DES

Economic burden

Clinical advantages of DES utilization are progressively apparent, essential worries about their expense have been brought up in the restorative group. The expanded expense of a DES is the last aftereffect of higher innovative work expenses of the assembling organizations. For the most part, the cost of a DES is no less than three-fold higher than the cost of a routine BMS, prompting a huge expansion of the underlying aggregate expense of the methodology. As indicated by information, the unhindered utilization of DES in all USA patients that as of now get standard BMS would cost the wellbeing framework about \$1.5 billion every year. In addition, the uniform change of all present standard BMS methodology to DES would bring about an underlying cost increment of about \$2800 per tolerant treated. Subsequently, the extraordinary practical effect on medicinal services spending plan, which is connected with the broad utilization of DES remains a significant issue, influencing overall financial strategy. The appearance of more assortments of DES in not so distant future will minimize the cost issue and make DES accessible to all patients.[28][29]

CONCLUSION

Both DES and DEB give viable treatment to coronary vein infection, a stent and inflatable must be deliverable and adaptable, cause insignificant injury to the vessel divider, cause negligible incendiary response, endothelialize well, give platform, and expansion for the vessel and at last advance vessel recuperating and re-demonstrating. Present accessible DES has fundamentally lessened the rate of restenosis; however, has expanded the cost three times higher than DEB, it has decreased horribleness, mortality. Patients no more need to return for heart catheterizations because of ISR. The achievement of present DES has moved the emphasis on further advancements toward improving long haul wellbeing and viability of these gadgets. The cutting-edge DES will most likely further enhance endothelialization and quick blood vessel mending, and will minimize the cost issue what's more, make DES accessible to all patients.

ACKNOWLEDGEMENT

Authors are thankful to the founder of our college Dr Patangrao kadam for providing the basic facility into the college, and also "Miss- Vishruti Kadam for her valuable guidance during review.

REFERENCES

1. John R. Laird, Barry T. Katzen et.al, Circulation cardiovascular intervention, 3(3), 2010: 268-276.
2. Mueller RL, Sanborn TA. The history of interventional cardiology: cardiac catheterization, angioplasty and related interventions. Am Heart J 1995; 129:160.

3. Alfonso F, Sandoval J, Perez-Vizcayno MJ, Cardenas A, Gonzalo N, Jimenez-Quevedo P, et al. Mechanisms of balloon angioplasty and repeat stenting in patients with drug-eluting in stent restenosis. *Int J Cardiol* 2015; 178:213–20.
4. L. Mauri, T.S. Silbaugh, P. Garg, R.E. Wolf, K. Zelevinsky, A. Lovett, *et al.* Drug-eluting or bare-metal stents for acute myocardial infarction *N Engl J Med* ,2008; 359: 1330–1342
5. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. *N Engl J Med*-2015;373: 1905–15.
6. G.W. Stone, A. Rizvi, W. Newman, K. Mastali, J.C. Wang, R. Caputo, et al., Everolimus eluting versus paclitaxel-eluting stents in coronary artery disease, *N. Engl. J. Med.*2010 362:1663–1674
7. A. Kastrati, J. Mehilli, N. von Beckerath, A. Dibra, J. Hausleiter, J. Pache, *et al.* Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. 2005, 293: 165–171
8. Menown IB, Noad R, Garcia EJ, Meredith I. The platinum chromium element stent platform: from alloy, to design, to clinical practice. *Adv Ther* 2010; 27:129-141
9. Meredith IT, Teirstein PS, Bouchard A, et al. Three-year results comparing platinum-chromium PROMUS element and cobalt-chromium XIENCE V everolimus-eluting stents in de novo coronary artery narrowing (from the PLATINUM trial). *Am J Cardiol* 2014; 113:1117–23
10. Garg S, Bourantas C, Serruys PW. New concepts in the design of drug-eluting coronary stents. *Nat Rev Cardiol* 2013; 10:248–60.
11. Chan MY, Sun JL, Newby LK, et al. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. *Circulation* 2009; 119:3110–7.
12. Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. *J Am Coll Cardiol* 2012; 59:1362–70.
13. Separham, B. Sohrabi, N. Aslanabadi, S. Ghaffari. The twelve-month outcome of biolimus eluting stent with biodegradable polymer compared with an everolimus eluting stent with durable polymer, *J. Cardiovasc. Thorac. Res.* 2011; 3: 113–116.
14. P.C. Smits, S. Hofma, M. Togni, et al., Abluminal biodegradable polymer biolimuseluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial, *Lancet* 2013; 381: 651–660.
15. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. *Lancet* 2008; 372:1163–73.
16. Y. Suzuki, F. Ikeno, T. Koizumi, F. Tio, A.C. Yeung, P.G. Yock, P.J. Fitzgerald, W.F. Fearon, In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation, *JACC Cardiovasc. Interv.* 2008; 1:168–173 .
17. G.A. Sgueglia, N. Foin, D. Todaro, A. Stipo, J.E. Davies, A. Gaspardone, C. Di Mario, E. Pucci, first optical coherence tomography follow-up of coronary bifurcation lesions treated by drug-eluting balloons, *J Invasive Cardiol*, 27 (2015) 191-198.
18. Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel eluting balloon catheter in patients with sirolimus-eluting stent restenosis. *J Am Coll Cardiol Intv* 2011; 4:149–54.

19. Rittger H, Brachmann J, Sinha AM, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. *J Am Coll Cardiol* 2012; 59:1377–82.
20. Indermuehle A, Bahl R, Lansky AJ, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. *Heart* 2013; 99:327–33.
21. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. *Lancet* 2013; 381:461–7.
22. N.E. Van Popele, D.E. Grobbee, M.L. Bots, et al., Association between arterial stiffness and atherosclerosis. *The Rotterdam study, Stroke* 32 (2011) 454–460.
23. Rubin J, Blaha MJ, Budoff MJ, et al. The relationship between resting heart rate and incidence and progression of coronary artery calcification: The Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis* 2012; 220:194- 200.
24. Van den Oord SCH, Sijbrands EJG, ten Kate GL, et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. *Atherosclerosis* 2013; 228:1-11.
25. Wildgruber MG, Berger HJ. Cryoplasty for the prevention of arterial restenosis. *Cardiovasc Intervent Radiol* 2008; 31:1050–8.
26. Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of Everolimus-eluting vs bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. *J Vasc Surg* 2012; 55:390–9.
27. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patientyears of follow-up from randomized trials. *Circulation*. 2012; 125:2873–2891.
28. Bischof M, Briel M, Bucher HC, Nordmann A. Cost-effectiveness of drug-eluting stents in a US medicare setting: a cost–utility analysis with 3-year clinical follow-up data. *Value Health* 2009; 5:649–56.
29. Bakhai A, Stone G, Mahoney E, et al. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV trial. *J Am Coll Cardiol* 2006; 48:253–61.